A five-year prospective study of fatigue in primary Sjögren's syndrome

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Haldorsen, Karstein ^a,b   Bjelland, Ingvar ^b,c   Bolstad, Anne Isine ^b   Jonsson, Roland ^a,c   Brun, Johan Gorgas ^b,c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; SJOGREN SYNDROME A ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; ENZYME ACTIVATION; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SHORT FORM 36; SJOEGREN SYNDROME; VISUAL ANALOG SCALE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE;

ADULT; AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SJOGREN'S SYNDROME; YOUNG ADULT;

EID: 80053923669     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3487     Document Type: Article

References (30)

1. Jonsson R, Bolstad AI, Brokstad KA, Brun JG: Sjögren's syndrome-a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci 2007, 1108:433-447
2. Krupp LB, Pollina DA: Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996, 9:456-460
3. Hartkamp A, Geenen R, Bijl M, Kruize AA, Godaert GL, Derksen RH: Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjögren's syndrome. Ann Rheum Dis 2004, 63:1335-1337
4. Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, Patel K, Novitzke J, Rohrer M, Gopalakrishnan R, Myers S, Nazmul-Hossain A, Emamian E, Huang A, Rhodus N, Moser K: Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. Arthritis Rheum 2008, 59:1780-1787
5. Lerdal A, Wahl A, Rustoen T, Hanestad BR, Moum T: Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health 2005, 33:123-130
6. Pillemer SR, Smith J, Fox PC, Bowman SJ: Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol 2005, 32:143-149
7. Campar A, Isenberg DA: Primary Sjögren's syndrome activity and damage indices comparison. Eur J Clin Invest 2010, 40:636-644
8. Tzioufas AG, Tsonis J, Moutsopoulos HM: Neuroendocrine dysfunction in Sjögren's syndrome. Neuroimmunomodulation 2008, 15:37-45
9. Theander L, Strombeck B, Mandl T, Theander E: Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren's syndrome? Rheumatology (Oxford) 2010, 49:1177-1183
10. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P: Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008, 67:1541-1544
11. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H: Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968
12. Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F, Markusse HM: Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 1998, 57:291-295
13. Harboe E, Tjensvoll AB, Vefring HK, Goransson LG, Kvaloy JT, Omdal R: Fatigue in primary Sjögren's syndrome-a link to sickness behaviour in animals? Brain Behav Immun 2009, 23:1104-1108
14. Theander E, Andersson SI, Manthorpe R, Jacobsson LT: Proposed core set of outcome measures in patients with primary Sjögren's syndrome: 5 year follow up. J Rheumatol 2005, 32:1495-1502
15. Baturone R, Soto MJ, Marquez M, Macias I, de Oca MM, Medina F, Chozas N, García-Pérez S, Girón-González JA: Health-related quality of life in patients with primary Sjögren's syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol 2009, 38:386-389
16. d'Elia HF, Bjurman C, Rehnberg E, Kvist G, Konttinen YT: Interleukin 6 and its soluble receptor in a central role at the neuroimmunoendocrine interface in Sjögren syndrome: an explanatory interventional study. Ann Rheum Dis 2009, 68:285-286
17. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's Syndrome: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558
18. Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA: Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome. Rheumatology (Oxford) 2009, 48:1102-1106
19. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123
20. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J: Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005, 32:811-819
21. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483
22. Dupont WD, Plummer WD Jr: PS: Power and sample size calculation. 2009 [http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize], Version 3.0
23. Peyre H, Leplège A, Coste J: Missing data methods for dealing with missing items in quality of life questionnaires. A comparison by simulation of personal mean score, full information maximum likelihood, multiple imputation, and hot deck techniques applied to the SF-36 in the French 2003 decennial health survey. Qual Life Res 2010, 20:287-300
24. Goligher EC, Pouchot J, Brant R, Kherani RB, Aviña-Zubieta JA, Lacaille D, Lehman AJ, Ensworth S, Kopec J, Esdaile JM, Liang MH: Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol 2008, 35:635-642
25. Bowman SJ: Patient-reported outcomes including fatigue in primary Sjögren's syndrome. Rheum Dis Clin North Am 2008, 34:949-962, ix
26. Bjerrum K, Prause JU: Primary Sjögren's syndrome: a subjective description of the disease. Clin Exp Rheumatol 1990, 8:283-288
27. Haldorsen K, Moen K, Jacobsen H, Jonsson R, Brun JG: Exocrine function in primary Sjögren syndrome: natural course and prognostic factors. Ann Rheum Dis 2008, 67:949-954
28. Champey J, Corruble E, Gottenberg JE, Buhl C, Meyer T, Caudmont C, Bergé E, Pellet J, Hardy P, Mariette X: Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 2006, 55:451-457
29. Brun JG, Madland TM, Gjesdal CB, Bertelsen LT: Sjögren's syndrome in an out-patient clinic: classification of patients according to the preliminary European criteria and the proposed modified European criteria. Rheumatology (Oxford) 2002, 41:301-304
30. Bax HI, Vriesendorp TM, Kallenberg CG, Kalk WW: Fatigue and immune activity in Sjögren's syndrome. Ann Rheum Dis 2002, 61:284